Compare LATA & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LATA | NGEN |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.7M | 197.5M |
| IPO Year | N/A | N/A |
| Metric | LATA | NGEN |
|---|---|---|
| Price | $10.10 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 44.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.91 | $1.70 |
| 52 Week High | $10.13 | $5.93 |
| Indicator | LATA | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.38 | 39.25 |
| Support Level | $9.91 | $1.70 |
| Resistance Level | $10.12 | $4.44 |
| Average True Range (ATR) | 0.01 | 0.18 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 50.00 | 56.59 |
Galata Acquisition Corp II is a blank check company.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.